Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
OT Pharmaceuticals AB
AB
Active
Org 5569195463
Kanalvägen 61, 191 34
Sollentuna
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2013 · 13 years old
1 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
OT Pharmaceuticals AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
5M
4M
2M
1M
0M
2021: 2M
2M
2021
2022: 1M (-50% vs 2021)
1M
-50%
2022
2023: 1M (0% vs 2022)
1M
0%
2023
2024: 3M (+200% vs 2023)
3M
+200%
2024
2025: 4M (+33% vs 2024)
4M
+33%
2025
EBITDA
SEK millions
1M
1M
1M
0M
0M
2021: 1M
1M
2021
2022: 1M (0% vs 2021)
1M
0%
2022
2023: 0M (-100% vs 2022)
0M
-100%
2023
2024: 0M
0M
2024
2025: 1M
1M
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2021
Revenue
4 096
3 136
1 015
1 481
1 588
Staff expenses
−2 048
−1 649
−350
−326
—
EBITDA
1 179
464
302
1 068
1 238
Depreciation & amort.
—
—
−49
−65
−65
EBIT
1 179
464
253
1 003
1 173
Net financials
48
−37
−452
−65
−110
Profit before tax
1 227
426
1
738
1 162
Tax
−253
−100
−100
−168
−265
Net profit
974
326
−99
570
897
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2021
Total assets
2 565
1 861
1 575
1 298
1 729
Equity
2 138
1 164
838
937
1 147
Long-term debt
—
—
—
—
0
Short-term debt
426
696
736
161
582
Total debt
426
696
736
161
582
Financial ratios
5-year trend
EBITDA margin
28,8 %
This company
15,8 %
Market median
This company
Market median
82% above market
2021
2025
Equity ratio
83,4 %
This company
38,2 %
Market median
This company
Market median
118% above market
2021
2025
Return on equity
45,5 %
This company
18,4 %
Market median
This company
Market median
147% above market
2021
2025
Net profit margin
23,8 %
This company
8,1 %
Market median
This company
Market median
194% above market
2021
2025
Asset turnover
1,60×
This company
1,12×
Market median
This company
Market median
43% above market
2021
2025
Debt / equity
0,20×
This company
0,62×
Market median
This company
Market median
68% below market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on OT Pharmaceuticals AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
